Cargando…

The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004

BACKGROUND: The widespread use of antiretroviral therapies has led to considerable concerns about the prevalence of drug-resistant, as transmission of drug-resistant (TDR) strains poses a challenge for the control of the HIV-1 epidemic. METHODS: We conducted an epidemiological study enrolling treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hanping, Chang, Shuai, Han, Yang, Zhuang, Daomin, Li, Lin, Liu, Yongjian, Liu, Siyang, Bao, Zuoyi, Zhang, Wenfu, Song, Hongbin, Li, Taisheng, Li, Jingyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080753/
https://www.ncbi.nlm.nih.gov/pubmed/27782811
http://dx.doi.org/10.1186/s12879-016-1928-x
_version_ 1782462786220064768
author Li, Hanping
Chang, Shuai
Han, Yang
Zhuang, Daomin
Li, Lin
Liu, Yongjian
Liu, Siyang
Bao, Zuoyi
Zhang, Wenfu
Song, Hongbin
Li, Taisheng
Li, Jingyun
author_facet Li, Hanping
Chang, Shuai
Han, Yang
Zhuang, Daomin
Li, Lin
Liu, Yongjian
Liu, Siyang
Bao, Zuoyi
Zhang, Wenfu
Song, Hongbin
Li, Taisheng
Li, Jingyun
author_sort Li, Hanping
collection PubMed
description BACKGROUND: The widespread use of antiretroviral therapies has led to considerable concerns about the prevalence of drug-resistant, as transmission of drug-resistant (TDR) strains poses a challenge for the control of the HIV-1 epidemic. METHODS: We conducted an epidemiological study enrolling treatment-naïve HIV-1-positive subjects at the Peking Union Medical College Hospital since 1991. Drug resistance was determined by submitting the sequences to the Stanford University Network HIV-1 database. RESULTS: Of 521 participants, 478 samples were amplified and sequenced successfully. HIV Transmitted drug resistance prevalence in China was determined to be 6.7 %. We did not find significant differences in the TDR rate by demographic characteristics. No significant time trend in the prevalence of overall TDR was observed (p > 0.05). CONCLUSIONS: We identified an intermediate prevalence of transmitted drug resistance (TDR), exhibiting a stable time trend. These findings enhance our understanding of HIV-1 drug resistance prevalence and time trend, and provide some guidelines for the comprehensive public health strategy of TDR prevention.
format Online
Article
Text
id pubmed-5080753
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50807532016-10-31 The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004 Li, Hanping Chang, Shuai Han, Yang Zhuang, Daomin Li, Lin Liu, Yongjian Liu, Siyang Bao, Zuoyi Zhang, Wenfu Song, Hongbin Li, Taisheng Li, Jingyun BMC Infect Dis Research Article BACKGROUND: The widespread use of antiretroviral therapies has led to considerable concerns about the prevalence of drug-resistant, as transmission of drug-resistant (TDR) strains poses a challenge for the control of the HIV-1 epidemic. METHODS: We conducted an epidemiological study enrolling treatment-naïve HIV-1-positive subjects at the Peking Union Medical College Hospital since 1991. Drug resistance was determined by submitting the sequences to the Stanford University Network HIV-1 database. RESULTS: Of 521 participants, 478 samples were amplified and sequenced successfully. HIV Transmitted drug resistance prevalence in China was determined to be 6.7 %. We did not find significant differences in the TDR rate by demographic characteristics. No significant time trend in the prevalence of overall TDR was observed (p > 0.05). CONCLUSIONS: We identified an intermediate prevalence of transmitted drug resistance (TDR), exhibiting a stable time trend. These findings enhance our understanding of HIV-1 drug resistance prevalence and time trend, and provide some guidelines for the comprehensive public health strategy of TDR prevention. BioMed Central 2016-10-26 /pmc/articles/PMC5080753/ /pubmed/27782811 http://dx.doi.org/10.1186/s12879-016-1928-x Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Li, Hanping
Chang, Shuai
Han, Yang
Zhuang, Daomin
Li, Lin
Liu, Yongjian
Liu, Siyang
Bao, Zuoyi
Zhang, Wenfu
Song, Hongbin
Li, Taisheng
Li, Jingyun
The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004
title The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004
title_full The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004
title_fullStr The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004
title_full_unstemmed The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004
title_short The prevalence of drug resistance among treatment-naïve HIV-1-infected individuals in China during pre- and post- 2004
title_sort prevalence of drug resistance among treatment-naïve hiv-1-infected individuals in china during pre- and post- 2004
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080753/
https://www.ncbi.nlm.nih.gov/pubmed/27782811
http://dx.doi.org/10.1186/s12879-016-1928-x
work_keys_str_mv AT lihanping theprevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT changshuai theprevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT hanyang theprevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT zhuangdaomin theprevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT lilin theprevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT liuyongjian theprevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT liusiyang theprevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT baozuoyi theprevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT zhangwenfu theprevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT songhongbin theprevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT litaisheng theprevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT lijingyun theprevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT lihanping prevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT changshuai prevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT hanyang prevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT zhuangdaomin prevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT lilin prevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT liuyongjian prevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT liusiyang prevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT baozuoyi prevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT zhangwenfu prevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT songhongbin prevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT litaisheng prevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004
AT lijingyun prevalenceofdrugresistanceamongtreatmentnaivehiv1infectedindividualsinchinaduringpreandpost2004